Clinical Trials
27
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (23 trials with phase data)• Click on a phase to view related trials
News
bluebird bio Strengthens Leadership Team with Three Key Executive Appointments
bluebird bio, a pioneer in gene therapies for severe genetic diseases, has appointed three new executives to strengthen its leadership team as the company focuses on commercial execution.
Protein Therapeutics Market Surges to $400 Billion as 20 New Drugs Gain Approval in 2023
The global protein therapeutics market reached an estimated $400 billion in value, driven by increasing pharmaceutical company investment in advanced protein-based drug development strategies.
Novartis's Oral MS Drug FTY720 Shows Promising Two-Year Efficacy Data, Potential 2010 Launch
• Novartis's experimental oral multiple sclerosis drug FTY720 (fingolimod) demonstrated significant reduction in disease relapses and progression over a two-year study period compared to placebo. • The lower 0.5mg dose showed comparable efficacy to higher doses with improved safety profile, leading Novartis to pursue regulatory approval for this dosage. • Novartis plans simultaneous FDA and EU submissions by end of 2009, with potential US market launch as early as 2010 pending expedited review.